Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis-Reference-Cited by-同舟云学术

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis

Published:2018-07-02 Issue:12 Volume:24 Page:2494-2500
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Mahadevan Uma¹,Dubinsky Marla C²,Su Chinyu³,Lawendy Nervin³,Jones Thomas V³,Marren Amy³,Zhang Haiying³,Graham Daniela⁴,Clowse Megan E B⁵,Feldman Steven R⁶,Baumgart Daniel C⁷

Affiliation:

1. University of California, San Francisco, California

2. Icahn School of Medicine at Mount Sinai, New York, New York

3. Pfizer Inc, Collegeville, Pennsylvania

4. Pfizer Inc, Groton, Connecticut

5. Duke University School of Medicine, Durham, North Carolina

6. Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina

7. Department of Gastroenterology and Hepatology, Charité Medical Center Virchow Hospital, and Medical School of the Humboldt University of Berlin, Berlin, Germany

Funder

Pfizer Inc.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/24/12/2494/26864036/izy160.pdf

Reference30 articles.

1. A meta-analysis on the influence of inflammatory bowel disease on pregnancy;Cornish;Gut,2007

2. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden;Stephansson;Inflamm Bowel Dis,2011

3. The effects of active IBD during pregnancy in the era of novel IBD therapies;de Lima-Karagiannis;Am J Gastroenterol,2016